Prognostic value of high on-treatment platelet reactivity ( Author`s Reply )

References (5)

1. Tekkeşin Aİ, Kaya A, Çakıllı Y, Türkkan C, Hayıroğlu Mİ, Borklu EB, et al. The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions. Anatol J Cardiol 2016; 16: 967-73
2. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762-71
3. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D\'Ascenzo F, et al. Stent thrombosis with drug-eluting and baremetal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-402
4. Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209-15
5. Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011; 161: 383-90.